Interaksi Galantamin

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (label Piridostigmin, Kontraindikasi)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (label Disikloverin, Peringatan dan perhatian)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (label Esmolol, Interaksi obat)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (label Fisostigmin, Interaksi obat)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (label Kokain, Interaksi obat)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (label Oksibutinin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (label Prokainamid, Peringatan)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (label Galantamin, Peringatan dan perhatian)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (label Galantamin, Peringatan dan perhatian)

When Phase II block is suspected in cases of prolonged neuromuscular blockade, positive diagnosis should be made by peripheral nerve stimulation, prior to administration of any anticholinesterase drug. (label Suksinilkolin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Deksametason, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (label Dipiridamol, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (label Galantamin, Interaksi obat)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Metilprednisolon, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednisolon, Interaksi obat)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Triamsinolon, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (label Galantamin, Interaksi obat)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (label Galantamin, Peringatan dan perhatian)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (label Risperidon, Interaksi obat)